Successful use of recombinant factor VII in massive hemoptysis due to community-acquired pneumonia

Chest. 2006 Aug;130(2):577-9. doi: 10.1378/chest.130.2.577.

Abstract

Recombinant activated factor VII (rFVIIa) is a powerful hemostatic agent developed for use in hemophilia. It has been used increasingly in life-threatening hemorrhage in a variety of other settings in which conventional medical or surgical therapy is unsuccessful. This report describes the successful use of rFVIIa for pulmonary hemorrhage due to a focal bleeding source in a regional hospital where bronchial artery embolization or surgery were not available. rFVIIa may be a useful temporizing measure in the unstable patient with pulmonary hemorrhage without coagulopathic bleeding when conventional treatment is not immediately available.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchography
  • Bronchoscopy
  • Diagnosis, Differential
  • Factor VII / therapeutic use*
  • Factor VIIa
  • Follow-Up Studies
  • Hemoptysis / diagnosis
  • Hemoptysis / drug therapy*
  • Hemoptysis / etiology
  • Humans
  • Male
  • Middle Aged
  • Pneumonia / complications*
  • Pneumonia / diagnosis
  • Recombinant Proteins / therapeutic use
  • Severity of Illness Index

Substances

  • Recombinant Proteins
  • Factor VII
  • recombinant FVIIa
  • Factor VIIa